Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Colorcon
Baxter
Express Scripts
Johnson and Johnson

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR FLONASE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Flonase

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00119015 ↗ The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis Terminated Merck Sharp & Dohme Corp. Phase 4 2005-07-01 Some people with nasal allergy symptoms continue to have symptoms even after treatment with a nasal steroid spray. The purpose of this study is to see if these patients are helped by adding another medication (montelukast) to their treatment compared to placebo (a substance that looks like the active medication but does not contain the drug).
NCT00119015 ↗ The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis Terminated University of Chicago Phase 4 2005-07-01 Some people with nasal allergy symptoms continue to have symptoms even after treatment with a nasal steroid spray. The purpose of this study is to see if these patients are helped by adding another medication (montelukast) to their treatment compared to placebo (a substance that looks like the active medication but does not contain the drug).
NCT00275561 ↗ Topical Steroid Treatment for Eosinophilic Esophagitis Completed Mayo Clinic Phase 2 2005-11-01 This was a randomized controlled trial of swallowed fluticasone vs. placebo for eosinophilic esophagitis. Eosinophilic esophagitis is an inflammatory condition in which the wall of the esophagus becomes filled with large numbers of eosinophils, a type of white blood cell. Patients who have this condition have difficulty in swallowing (dysphagia) solid food. Prior to treatment the patients had biopsies of their esophagus and took questionnaires regarding their symptoms. Treatment was given for 6 weeks, after which biopsies were taken from the esophagus to measure any changes in the tissue from before treatment. The primary endpoint was improvement in dysphagia as measured by the validated Mayo Dysphagia Questionaire. Secondary outcomes included partial symptom response, and histologic (tissue) response to treatment.
NCT00385463 ↗ Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Receiving Advair Diskus or Placebo Withdrawn GlaxoSmithKline N/A 2006-04-01 The four respiratory drugs being researched in this study have been approved by the US Food and Drug Administration (FDA) and are currently available by prescription at your drug store. One of the drugs is for the treatment of asthma alone, one is for treatment of SAR alone, and one is for treatment of both SAR and asthma. In addition, you will also receive one asthma rescue drug (albuterol) that is to be used for any breakthrough asthma symptoms that you may experience throughout the study. The purpose of this study is to see how well your asthma and SAR are controlled when taking one of the medicine combinations
NCT00385463 ↗ Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Receiving Advair Diskus or Placebo Withdrawn Creighton University N/A 2006-04-01 The four respiratory drugs being researched in this study have been approved by the US Food and Drug Administration (FDA) and are currently available by prescription at your drug store. One of the drugs is for the treatment of asthma alone, one is for treatment of SAR alone, and one is for treatment of both SAR and asthma. In addition, you will also receive one asthma rescue drug (albuterol) that is to be used for any breakthrough asthma symptoms that you may experience throughout the study. The purpose of this study is to see how well your asthma and SAR are controlled when taking one of the medicine combinations
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Flonase

Condition Name

Condition Name for Flonase
Intervention Trials
Allergic Rhinitis 5
Seasonal Allergic Rhinitis 4
Rhinitis 2
Conjunctivitis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Flonase
Intervention Trials
Rhinitis 14
Rhinitis, Allergic 13
Rhinitis, Allergic, Seasonal 5
Sinusitis 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Flonase

Trials by Country

Trials by Country for Flonase
Location Trials
United States 24
Canada 1
Ireland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Flonase
Location Trials
California 3
New York 2
Missouri 2
Massachusetts 2
Florida 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Flonase

Clinical Trial Phase

Clinical Trial Phase for Flonase
Clinical Trial Phase Trials
Phase 4 8
Phase 3 7
Phase 2/Phase 3 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Flonase
Clinical Trial Phase Trials
Completed 16
Terminated 3
Withdrawn 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Flonase

Sponsor Name

Sponsor Name for Flonase
Sponsor Trials
Merck Sharp & Dohme Corp. 7
GlaxoSmithKline 2
Stanford University 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Flonase
Sponsor Trials
Industry 15
Other 13
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Mallinckrodt
Medtronic
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.